Bristol-Myers Squibb and AstraZeneca Company Profile

News Articles [ 2274 Associated News Articles listed on BioPortfolio]

Bristol-Myers Squibb and AstraZeneca complete expansion of diabetes alliance

Bristol-Myers Squibb Company (NYSE:BMY) and AstraZeneca (LSE:AZN) announced that following the successful completion of the acquisition of Amylin Pharmaceuticals by Bristol-Myers Squibb, AstraZeneca h...

Bristol-Myers Squibb and AstraZeneca Complete Expansion of Diabetes Alliance Through Bristol-Myers Squibb's Acquisition of Amylin

PRINCETON, N.J. & LONDON--(BUSINESS WIRE)--Aug 9, 2012 - Bristol-Myers Squibb Company (NYSE:BMY) and AstraZeneca (LSE:AZN) announced that following the successful completion of the acquisition o...

Bristol-Myers Squibb completes acquisition of Amylin

Bristol-Myers Squibb Company and AstraZeneca announced that following the successful completion of the acquisition of Amylin Pharmaceuticals by Bristol-Myers Squibb, AstraZeneca has made an initial pa...

Bristol-Myers, AstraZeneca expand diabetes alliance

Bristol-Myers Squibb Company and AstraZeneca have announced the completion of the acquisition of Amylin Pharmaceuticals by Bristol-Myers Squibb.

Dealmakers weekly review – July 3 2012 – Amylin, Bristol-Myers Squibb, AstraZeneca, Biogen Idec, Celgene, Inhibrx

BMS acquires Amylin and then collabroates with AstraZeneca on diabetes franchise dominates the weeks dealmaking The review The major deal story from last week was the $5.3 billion acquisition of Amyli...

BMS and AstraZeneca to promote diabetes product portfolio

Bristol-Myers Squibb and AstraZeneca announced today that, following the completion of Bristol-Myers Squibb’s acquisition of Amylin, the companies will enter into collaboration arrangements, based o...

TEXT-S&P comments on Bristol-Myers Squibb Co

July 2 - Standard & Poor's Ratings Services said today that Bristol-Myers Squibb Co.'s (A+/Stable/A-1+) $7.0 billion cash acquisition of unrated Amylin Pharmaceuticals will not affect its ratings or...

Where We Are Headed -- New Outlook on Bristol-Myers Squibb Company and AstraZeneca Plc

JAKARTA, INDONESIA -- (Marketwire) -- 10/24/12 -- Moments ago, NationalTradersAssociation.org introduced new coverage of Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca Plc (NYSE: AZN). Fu...

Drugs and Medications [ 118 Associated Drugs and Medications listed on BioPortfolio]

Picot plus [Bristol-Myers Squibb de Mexico, S. de R.L. de C.V.]

picot plus Antacid and pain reliever

Sal de uvas picot [Bristol-Myers Squibb de Mexico, S. de R.L. de C.V.]

Sal de Uvas Picot Antacid

Sal de uvas picot [Bristol-Myers Squibb de Mexico, S. de R.L. de C.V.]

Sal de Uvas Picot Antacid

Sal de uvas picot [Bristol-Myers Squibb de Mexico, S. de R.L. de C.V.]

Sal de Uvas Picot Antacid

Capitrol (chloroxine 2%) shampoo [Bristol-Myers Squibb]

Capitrol (chloroxine 2%) Shampoo

PubMed Articles [ 816 Associated PubMed Articles listed on BioPortfolio]

Efficient and scalable enantioselective synthesis of a CGRP antagonist.

An enantioselective synthesis of the CGRP antagonist BMS-846372, amenable to large scale preparation, is presented. This new synthesis showcases a chemo- and enantioselective reduction of a cyclohepta...

In Process Citation.

Deal watch: Bristol-Myers Squibb invests in cancer antibody that targets the innate immune system.

Novel pyrrolo2,1-f1,2,4triazin-4-amines: Dual inhibitors of EGFR and HER2 protein tyrosine kinases.

A novel series of 5-((4-aminopiperidin-1-yl)methyl)-pyrrolo[2,1-f][1,2,4]triazin-4-amines with small aniline substituents at the C4 position were optimized for dual EGFR and HER2 protein tyrosine kina...

A contrast in safety, pharmacokinetics, and pharmacodynamics across age groups after a single 50-mg oral dose of the γ-secretase inhibitor avagacestat.

Aim: To evaluate the single-dose pharmacokinetics, pharmacodynamics, and preliminary tolerability of the γ-secretase inhibitor BMS-708163 (avagacestat) in young and elderly men and women. Methods: Al...

Clinical Trials [ 65 Associated Clinical Trials listed on BioPortfolio]

Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Metformin HCl (1000 mg), Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Glucophage®, Bristol-Myers Squibb Company) in Fed, Healthy, Adult Subjects

- Objective: - A Randomized, Two-Way Crossover, Single-Dose, Open-Label Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Metformin HCl (1000 mg), Co...

Bioequivalence Study of Cefprozil Tablets, USP 500 mg Undef Fed Conditions

The objective of this study is to assess the single - dose relative bioavailability of Ranbaxy and Bristol-Myers Squibb Company (CEFZIL ®) 500 mg cefprozil tablets, under fed conditions.

Bioavailability Study of (Buspar) Buspirone HCl Tablets Under Fasting and Fed Conditions

To compare the single-dose bioavailability of Par and Bristol-Myers Squibb Buspirone HCl Tablets

Bioequivalence Study of Pravastatin Sodium Tablets 80 mg Under Fasting Conditions

This is a single Dose Two-Way Crossover Fasting Bioequivalence Study of Pravastatin 80 mg Tablets of Dr.Reddy's Laboratories Limited with Pravachol 80 mg, Bristol Myers Squibb in Healthy V...

Food Study Metformin Hydrochloride ER Tablets 750 mg and Glucophage XR 750 mg

The objective of this study was to investigate the bioequivalence of Mylan's metformin hydrochloride ER tablets to Bristol-Myers Squibb's Glucophage® XR tablets following a single, oral 7...

Companies [ 135 Associated Companies listed on BioPortfolio]

Bristol-Myers Squibb Company & AstraZeneca

Bristol-Myers Squibb and AstraZeneca entered into a collaboration in January 2007 to enable the companies to research, develop and commercialize select investigational drugs for t...

Bristol-Myers Squibb Company and AstraZeneca

Bristol-Myers Squibb and AstraZeneca entered into a collaboration in January 2007 to enable the companies to research, develop and commercialize select investigational drugs for t...

Bristol-Myers Squibb and AstraZeneca

Bristol-Myers Squibb and AstraZeneca entered into a collaboration in January 2007 to enable the companies to research, develop and commercialize select investigational drugs for t...

AstraZeneca & Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more informa...

Bristol-Myers Squibb Company

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases....